Close this search box.

Deals Report: Sanofi-Novavax to co-commercialize Nuvaxovid, develop combination vaccines


Plus: Maze finds Pompe disease program partner in Shionogi, and updates from Takeda-AC Immune, Sanofi-Fulcrum and more

By BioCentury Staff

May 14, 2024 12:14 AM UTC

Novavax struck a deal with Sanofi late last week that could be transformative for the company, nearly doubling the biotech’s market cap, and Maze found another taker for its Pompe program after FTC scrutiny sank a prior agreement. Meanwhile, AC Immune and Fulcrum partnered key pipeline programs early Monday.

Sanofi (Euronext:SAN; NASDAQ:SNY) agreed to pay $500 million up front to Novavax Inc. (NASDAQ:NVAX) for most global co-commercialization rights to the biotech’s Nuvaxovid vaccine for COVID-19, as well as rights to combine it with Sanofi’s own influenza vaccine in a combination shot. Sanofi is also paying about $70 million for an equity stake of less than 5%…